Study of tumor-shrinking drug before surgery for diffuse tenosynovial giant cell tumor
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests whether taking a new drug (pimicotinib) before surgery can shrink the tumor and make surgery more effective, compared to having surgery right away. It is for people with a type of benign but aggressive joint tumor called diffuse TGCT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with diffuse tenosynovial giant cell tumor (a type of joint tumor)
- Your doctor has said the tumor can be removed with surgery
- You have at least one tumor that is 2 centimeters or larger
- You have symptoms like pain or stiffness that scores at least 4 out of 10
- You have not taken a CSF1 or CSF1R inhibitor (a type of targeted therapy) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
This study tests an experimental drug (DCC-3014) for people with TGCT, a non-cancerous joint tumor. The drug may help reduce pain and improve joint movement without the risks of surgery.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This trial tests a new drug, SCTB39G, for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it can shrink tumors and improve survival, and to find the best dose. Participation involves regular treatment and check-ups.
This study tests an experimental medication (JMT103) for people with giant cell tumor of bone that cannot be safely removed with surgery. The drug may help shrink the tumor or slow its growth, providing an option when surgery is too risky.
Hear when a new Tenosynovial Giant Cell Tumor, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.